Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 9/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10122740 | 0.87 | TSHR (0.47) | L3MBTL1SMN1; SMN2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL3297985 | 0.87 | GRIN2D (0.45) | L3MBTL1SMN1; SMN2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL12957756 | 0.87 | NQO2 (0.48) | L3MBTL1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15031974 | 0.87 | MAPT (0.50) | L3MBTL1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL25428041 | 0.83 | GRIN2D (0.42) | L3MBTL1SMN1; SMN2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1770841 | 0.83 | POLB (0.56) | L3MBTL1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL680329 | 0.83 | POLB (0.61) | L3MBTL1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL298224 | 0.83 | POLB (0.59) | L3MBTL1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5859293 | 0.82 | TSHR (0.47) | L3MBTL1SMN1; SMN2NQO2TAAR1POLB | |
| SCHEMBL3215315 | 0.81 | KMT2A (0.44) | L3MBTL1SMN1; SMN2GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007625-A1 | Compounds for the Treatment of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2026-01-08 | — | — | US | disclosed |
| EP-4587418-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2025-07-23 | — | — | EP | disclosed |
| US-20250136620-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. | 2025-05-01 | — | — | US | disclosed |
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2024-09-05 | — | — | US | disclosed |
| US-20240124459-A9 | PRPK INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2024-04-18 | — | — | US | disclosed |
| WO-2024056865-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024056865-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2024-03-21 | — | — | WO | disclosed |
| US-20230271966-A1 | PRPK INHIBITORS | DANA FARBER CANCER INST INC (US) | 2023-08-31 | — | — | US | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023137225-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-03-26 | — | — | US | disclosed |
| US-7439350-B2 | Nucleotide analogs | GILEAD SCIENCES, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20070049537-A1 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
| US-20040242465-A1 | Nucleotide analogs | BISCHOFBERGER NORBERT W (US) | 2004-12-02 | — | — | US | disclosed |
| US-20010041794-A1 | Nucleotide analogs | GILEAD SCIENCES, INC. | 2001-11-15 | — | — | US | disclosed |
| US-6225460-B1 | PHOSPHOAMIDATE OR ESTER BOND THAT IS HYDROLYZED IN VIVO TO YIELD A CORRESPONDING PHOSPHONATE NUCLEOTIDE ANALOG. | GILEAD SCIENCES, INC. | 2001-05-01 | — | — | US | disclosed |
| US-5798340-A | ANTITUMOR/ANTINEOPLASTIC ACTIITY, VIRICIDES; BROAD SPECTRUM MICROBIOCIDES; THIOPHOSPHONATES HYDROLYZABLE IN VIVO; ORAL ADMINISTRATION; BIOAVAILABILITY; NONTOXIC; POTENCY | GILEAD SCIENCES, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| US-5656745-A | AMIDATE LINKAGE; ANTITUMOR, ANTICARCINOGENIC AGENTS | GILEAD SCIENCES, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242465-A1 | Nucleotide analogs | PNP, NUDT1, TYMP | L3MBTL1 1439/4885SMN1; SMN2 1750/4885GRIN2D 4291/4885 |
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | NLRP3, NLRP1, PYCARD | L3MBTL1 3143/4885SMN1; SMN2 4374/4885GRIN2D 3405/4885 |
| US-20260007625-A1 | Compounds for the Treatment of Neuromuscular Disorders | RYR1, CACNB1, CACNA1S | L3MBTL1 215/4885SMN1; SMN2 12/4885GRIN2D 670/4885 |
| US-20230271966-A1 | PRPK INHIBITORS | PRP4K, PRPS1, PRPF6 | L3MBTL1 2599/4885SMN1; SMN2 923/4885GRIN2D 4654/4885 |
| US-20010041794-A1 | Nucleotide analogs | PNP, NUDT1, TYMP | L3MBTL1 1439/4885SMN1; SMN2 1750/4885GRIN2D 4291/4885 |
| US-20070049537-A1 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | UGGT1, UGT2B7, G6PD | L3MBTL1 2121/4885SMN1; SMN2 3545/4885GRIN2D 2701/4885 |
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | NGF, BDNF, NTRK2 | L3MBTL1 4441/4885SMN1; SMN2 165/4885GRIN2D 201/4885 |
| US-20240124459-A9 | PRPK INHIBITORS | PRP4K, PRPS1, PRPF6 | L3MBTL1 2599/4885SMN1; SMN2 923/4885GRIN2D 4654/4885 |
| US-20250136620-A1 | BTK DEGRADER | BTK, CBL, LYN | L3MBTL1 1188/4885SMN1; SMN2 3356/4885GRIN2D 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.